HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Kicks Off Kratom Enforcement With $400,000 Seizure In Illinois

This article was originally published in The Tan Sheet

Executive Summary

The seizure targets some 90,000 bottles of RelaKzpro brand products marketed by Dordoniz Natural Products in Illinois, the home state of Sen. Dick Durbin, who is critical of FDA's supplement market enforcement and plans legislation for tighter regulation.

You may also be interested in...



FDA's Opioid Label For Kratom Called Misbranding By Marketers

"Based on the scientific information in the literature and further supported by our computational modeling and the reports of its adverse effects in humans, we feel confident in calling compounds found in kratom, opioids," says Commissioner Scott Gottlieb.

Health & Wellness Industry News Roundup: Week Of Aug. 1

Kratom seized again; FTC warns on Zika claims; EntereoMed passes 2 of 3 UK gut health claim checks; Bevolution adds Dr. Smoothie to lineup; physicians committee recommends prebiotics; and more news in brief.

Kratom Action Presents Regulatory Puzzle For FDA

The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel